The epidemiology and therapeutic options for the COVID-19

被引:12
作者
Li, Jingwei [1 ]
Shao, Jun [1 ]
Wang, Chengdi [1 ]
Li, Weimin [1 ]
机构
[1] Sichuan Univ, West China Hosp, West China Med Sch, Dept Resp & Crit Care Med, Chengdu 610041, Peoples R China
基金
中国国家自然科学基金;
关键词
coronavirus disease 2019; COVID-19; epidemiology; clinical features; treatment; CLINICAL CHARACTERISTICS; CORONAVIRUS; SARS-COV-2; WUHAN; TRANSMISSION; COMBINATION; TARGETS; VACCINE; BINDING; PROTEIN;
D O I
10.1093/pcmedi/pbaa017
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
An outbreak of coronavirus disease 2019 (COVID-19), a disease caused by a novel pneumonia virus, has affected over 200 countries and regions worldwide. With the increasing number of patients and deaths, WHO have declared it as a global pandemic currently, indicating a third large-scale epidemic coronavirus has appeared since the emergence of severe acute respiratory syndrome coronavirus (SARS) and Middle-East respiratory syndrome (MERS) in the twenty-first century. Considering the great harm it has caused, researchers throughout the world have been chasing to exploit the pathophysiology, characteristics, and potential remedies for COVID-19 to better battle the outbreak. Therefore, the current study revisits advances of the virology, epidemiology, clinical features, therapeutic options, and prevention of COVID-19. The features of asymptomatic carriers are also been explored.
引用
收藏
页码:71 / 84
页数:14
相关论文
共 140 条
[21]   Convalescent plasma as a potential therapy for COVID-19 [J].
Chen, Long ;
Xiong, Jing ;
Bao, Lei ;
Shi, Yuan .
LANCET INFECTIOUS DISEASES, 2020, 20 (04) :398-400
[22]   Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study [J].
Chen, Nanshan ;
Zhou, Min ;
Dong, Xuan ;
Qu, Jieming ;
Gong, Fengyun ;
Han, Yang ;
Qiu, Yang ;
Wang, Jingli ;
Liu, Ying ;
Wei, Yuan ;
Xia, Jia'an ;
Yu, Ting ;
Zhang, Xinxin ;
Zhang, Li .
LANCET, 2020, 395 (10223) :507-513
[23]  
Chen T, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m1295, 10.1136/bmj.m1091]
[24]   Altered COVID-19 receptor ACE2 expression in a higher risk group for cerebrovascular disease and ischemic stroke [J].
Choi, Ji-Young ;
Lee, Hye-Kyung ;
Park, Jung Hyun ;
Cho, Sun-Jung ;
Kwon, Munjin ;
Jo, Chulman ;
Koh, Young Ho .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2020, 528 (03) :413-419
[25]   The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin [J].
Chorin, Ehud ;
Dai, Matthew ;
Shulman, Eric ;
Wadhwani, Lalit ;
Bar-Cohen, Roi ;
Barbhaiya, Chirag ;
Aizer, Anthony ;
Holmes, Douglas ;
Bernstein, Scott ;
Spinelli, Michael ;
Park, David S. ;
Chinitz, Larry A. ;
Jankelson, Lior .
NATURE MEDICINE, 2020, 26 (06) :808-809
[26]   Chloroquine for the 2019 novel coronavirus SARS-CoV-2 [J].
Colson, Philippe ;
Rolain, Jean-Marc ;
Raoult, Didier .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2020, 55 (03)
[27]  
Committee G. O. o. N. H, 2020, DIAGN TREATM PROGR N
[28]  
Corporation S, 2020, EVAL SAF TOL IMM BAC
[29]   Covid-19: four fifths of cases are asymptomatic, China figures indicate [J].
Day, Michael .
BMJ-BRITISH MEDICAL JOURNAL, 2020, 369 :m1375
[30]   Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study [J].
Deng, Lisi ;
Li, Chunna ;
Zeng, Qi ;
Liu, Xi ;
Li, Xinghua ;
Zhang, Haitang ;
Hong, Zhongsi ;
Xia, Jinyu .
JOURNAL OF INFECTION, 2020, 81 (01) :E1-E5